Sickle Cell DiseaseSymptoms, Doctors, Treatments, Advances & More
Sickle Cell Disease Overview
Learn About Sickle Cell Disease
St. Christopher's Pediatric Associates Hematology - E. Erie Avenue
. Dr. Apollonsky is rated as an Elite provider by MediFind in the treatment of Sickle Cell Disease. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Apollonsky is board certified in American Board Of Pediatrics.
Jefferson Hematology - Honickman Center
Sophie Lanzkron is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Lanzkron is rated as an Elite provider by MediFind in the treatment of Sickle Cell Disease. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Lanzkron is board certified in Hematology. Dr. Lanzkron is currently accepting new patients.
Atrium Health Levine Cancer Institute
Payal Desai is a Hematologist practicing medicine in Charlotte, North Carolina. Dr. Desai is rated as an Elite provider by MediFind in the treatment of Sickle Cell Disease. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Aspiration. Dr. Desai is board certified in American Board Of Internal Medicine, Hematology, 2012. Dr. Desai is currently accepting new patients.
Summary: This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells ...
Summary: This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to evaluate the safety and tolerability of CSL889 in study partici...


